Group 1: Company Developments - The company has received FDA approval for its innovative drug SIR-Spheres® for treating unresectable hepatocellular carcinoma (HCC) [1] - The company’s nasal spray product OC-01 for dry eye syndrome has been approved in mainland China and has begun commercial prescriptions [1][3] - OC-01 is the only nasal spray approved for treating dry eye syndrome in China, providing a new treatment option for patients [1] Group 2: Market Insights - The dry eye syndrome market in China is estimated to have around 360 million patients, with a prevalence rate of approximately 21.0% to 52.4% [3] - The overall dry eye syndrome market in China has a compound annual growth rate (CAGR) of 1.6% from 2017 to 2021, with moderate growth expected in the coming years [4] - The global dry eye syndrome market is projected to reach $25.48 billion in 2024, expanding at a CAGR of 3.4% to $33.26 billion by 2033 [6] Group 3: Product Advantages - OC-01 utilizes a nasal delivery method that enhances tear secretion and improves tear film stability, potentially increasing patient compliance compared to traditional eye drops [7] - The product has shown strong commercial potential, with over 97,000 prescriptions in the U.S. within its first year and approximately $42 million in sales revenue in 2023 [7] - The company has a comprehensive pipeline of innovative ophthalmic products, including treatments for various eye conditions, which are expected to contribute to future revenue growth [11][14] Group 4: Competitive Landscape - The ophthalmic drug market in China has grown from 15.1 billion RMB in 2016 to 18.8 billion RMB in 2020, with a projected market size of 44 billion RMB by 2025 [8] - The company is strategically positioned in the competitive ophthalmic market, focusing on innovative product development to maintain its leading position [10] - The company has established a professional marketing team and a nationwide distribution network to support its ophthalmic product sales [14]

Core Viewpoint - The stock price of Yuan Da Pharmaceutical has surged nearly 50% in May, reaching a historical high of 9.20 HKD, driven by positive news regarding its innovative ophthalmic drug GPN01768, which has been approved for market in Macau [1][3]. Group 1: Product Development and Market Potential - GPN01768 is the first and only FDA-approved drug for treating Demodex blepharitis, with exclusive rights for development, production, and commercialization in Greater China [3]. - The approval of GPN01768 in Macau is expected to facilitate its future launch in the Guangdong-Hong Kong-Macau Greater Bay Area and further promote its entry into mainland China [3]. - The global prevalence of Demodex blepharitis is significant, with an estimated 468 million patients in 2021, projected to increase to approximately 506 million by 2030 [4][6]. - GPN01768 has shown strong market penetration in the U.S., generating $180 million in revenue in 2024 and achieving $78.3 million in sales in Q1 2025, reflecting an 18% increase from the previous quarter [6][7]. Group 2: Clinical Need and Competitive Advantage - There is currently no specific treatment for Demodex blepharitis, highlighting the urgent need for effective therapies, which GPN01768 aims to address [6]. - GPN01768 acts as a selective non-competitive antagonist of the GABA-Cl channel in Demodex mites, leading to their paralysis and death, thus providing a targeted treatment option [6]. - The domestic market for blepharitis treatment is estimated to be around 1.85 billion RMB in 2023, indicating substantial commercial potential for GPN01768 in China [7]. Group 3: Innovation and Strategic Positioning - Yuan Da Pharmaceutical has established a comprehensive innovation framework across multiple business segments, particularly in ophthalmology, positioning itself as a "hidden leader" in the domestic market [8]. - The company has a robust pipeline of innovative products targeting various eye conditions, with several expected to receive approval in the next three years [8]. - The company’s nuclear medicine division has also made significant advancements, with a new facility set to enhance its production capabilities and meet growing market demands [14][15]. Group 4: Market Sentiment and Future Outlook - The capital market has recognized the company's innovative transformation, with multiple research institutions raising the stock price expectations, including a target price increase to 9.6 HKD by CICC and 10.15 HKD by Huatai Securities [14]. - The ongoing development of innovative products across various segments is anticipated to drive sustained growth and performance for the company [15].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本集團獲得治療乾眼症的全球首創創新產品的獨家開發及商業化權益 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，近日，本集團與箕星藥業香港有限公司(「箕星」)達成產品引進戰略 合作協議。根據協議，在相關條件滿足後，本集團將獲得用於治療乾眼症的全球首創創 新產品酒石酸伐尼克蘭鼻噴霧劑「( OC-01」)及 OC-02（Simpinicline）鼻噴霧劑「( OC-02」) 在大中華區（中國大陸、中國香港特別行政區、中國澳門特別行政區、台灣地區）的獨 家開發及商業化權益。此次戰略合作將進一步深化本集團在眼科領域的創新產品佈局。 箕星是一家總部位於美國和中國的生物科技公司，致力於將創新科學和藥物帶給罹患嚴 重危及生命健康的全球患者，其重磅產品 OC-01 和 OC-02 是兩種高選擇性的乙醯膽鹼 能受體激動劑，可通過啟動三叉神經副交感神經 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕大註冊成立之有限公司 ) （股份代號：00512） 自願性公告 本集團全球創新眼科藥物 GPN00833 完成國內ⅠⅠⅠ期臨床研究並達到了臨床終點 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，近日，本集團用於眼科術後抗炎鎮痛的激素納米混懸滴眼液 GPN00833 完成了在中國開展的 III 期臨床研究並成功達到了臨床終點，是本集團在五官科領域眼 科方向的又一次重大里程碑進展。 GPN00833 為抗炎鎮痛類激素納米混懸滴眼液，其主要活性成分丙酸氯倍他索是一種強 效的糖皮質激素，具有高效的局部抗炎活性和較強的毛細血管收縮作用，同時其獨特的 納米製劑工藝有效解決了激素產品低水溶性導致的生物利用度低及安全性風險。該產品 於二零二三 ...